Skip to content

PTSD: all studies

Page 72 of 211: studies 711 to 720 of 2,101, newest first. Back to the PTSD overview

Research

MDMA-Assisted Therapy for Complex-Post-Traumatic Stress Disorder: Toward a neurocognitive account

Philip Gerrans, Hugh Mgovern, Jakob Hohwy et al. 1 citation preprint

Complex post-traumatic stress disorder (C-PTSD) is a newly recognized diagnosis that is distinguished from post-traumatic stress disorder (PTSD) through additional symptom clusters beyond re-experiencing, avoidance, and a persistent sense of threat. In addition to these core PTSD symptoms, C-PTSD is characterized by disturbances in self-organization, including affective dysregulation, negative...

Brain State Dynamics in Ketamine-Induced Dissociation Resemble Those in PTSD

Noam Goldway, Taly Markovits, Naomi Fine et al. preprint

Dissociation, an altered state of consciousness in which individuals feel detached from their body, environment, and sense of self, is a common feature of Post-Traumatic Stress Disorder (PTSD). Despite its significance, the neurocognitive processes underlying dissociation remain poorly understood, potentially limiting the effectiveness of PTSD diagnostics and treatment. To address this gap, we...

At-Home Telehealth-Supported Subcutaneous Ketamine Therapy for Depression, Anxiety, and PTSD: A Real-World Observational Study of Safety, Feasibility, and Effectiveness in a Large Cohort (Preprint)

Acacia C Parks, Amanda L Woodward, Robert D Henry et al.

BACKGROUND Major Depressive Disorder (MDD), Generalized Anxiety Disorder (GAD), and Post-Traumatic Stress Disorder (PTSD) are leading global causes of disability. Standard interventions often suffer from slow mechanisms of action, high attrition, and significant accessibility barriers. While intravenous (IV) and intranasal ketamine have emerged as rapid-acting alternatives, their high cost and...

The Conceptual Framework for the Therapeutic Approach used in Phase 3 Trials of MDMA-AT for PTSD

Kelley C O'Donnell, Michael Alpert, Lauren Okano et al. preprint

Results from multiple recent studies support the use of 3,4-methylenedioxymethamphetamine (MDMA) in conjunction with psychotherapy (i.e., MDMA-Assisted Therapy) in the treatment of post-traumatic stress disorder (PTSD). In two Phase 3 trials, MDMA-Assisted Therapy comprised a short-term, intensive psychotherapy that included three sessions directly facilitated by MDMA (referred to as...

DOI: 10.31219/osf.io/gey78 (opens in new tab) Psychedelic-assisted therapy PTSD Treatment Trauma therapy Trauma care +21

Ketamine administration reduced conditioned defensive behaviour and upregulated protein expression associated with neuroplasticity in a planarian model of aversive memory reactivation.

Progress in neuro-psychopharmacology & biological psychiatry October 17, 2026 Fionnghuala L J James, Sayed K Ahamed, Cheng-I Yang et al.

Traumatic memories that are resistant to modification or extinction are a characteristic feature of post-traumatic stress disorder (PTSD). The process of fear memory reconsolidation has been identified as a potential therapeutic target for the treatment of PTSD. Ketamine, an NMDA receptor antagonist with dissociative properties, has been identified as a drug with high therapeutic potential for...

The Nova Protocol: a comprehensive multimodal longitudinal study among civilian survivors of a mass trauma event.

European Journal of Psychotraumatology September 14, 2026 Roee Admon, Ophir Netzer, Noa Magal et al.

Background: The 7 October 2023 attack in southern Israel was one of the deadliest terror attacks in modern history, with 1,182 fatalities, more than 4,000 wounded individuals, and 251 hostages. The Nova music festival, an all-night outdoor rave near the Gaza border, suffered the highest number of civilian casualties, with more than 370 festival attendees killed. Survivors were exposed to...

[The use of psychedelics in psychiatry].

Orvosi hetilap September 13, 2026 Szabolcs Kéri

Over the past five years, the literature on the psychiatric use of psychedelic and related treatments has expanded substantially. Several randomized controlled trials and pooled analyses have been conducted in mood disorders, treatment-resistant depression, and post-traumatic stress disorder. Trial methodology, however, remains a fundamental source of uncertainty, and despite the popularity of...

A Systematic Review of MDMA’s Effects on Social Cognition in Placebo-Controlled Trials

PsyArXiv Preprints September 11, 2026 preprint

Background 3,4-Methylenedioxymethamphetamine (MDMA) is associated with distinctive prosocial and empathogenic effects, yet the consistency and scope of its impact on social cognition in humans remain unclear. Although numerous placebo-controlled studies have examined MDMA’s acute social effects, findings vary widely across subjective and behavioural domains. Methods We conducted a systematic...

DOI: osf:sgdau_v3 (opens in new tab) Full text (opens in new tab) MDMA PTSD 3 4-methylenedioxymethamphetamine Empathy +12

Retreat from Racism: A Psychedelic Group Experience for Racial Stress and Trauma

Psychedelics July 1, 2026 Sergio Pérez Rosal, Sonya C. Faber, M. Myriah MacIntyre et al.

Background Racism and discrimination are pervasive social determinants of health, yet mainstream mental health care often fails to address the psychological sequelae of racial trauma, or race-based traumatic stress (RBTS). While psychedelic-assisted therapy (PAT) has re-entered the scientific mainstream, empirical guidance for culturally attuned, integrative care is limited. This study explores...

DOI: 10.1016/j.psyche.2026.100031 (opens in new tab) Stress linguistics Group periodic table Posttraumatic stress Ethnic group +2

Enhancing primary care detection and referral of nightmare disorder: a quality improvement initiative : Journal name: Sleep and Breathing.

Sleep & Breathing June 26, 2026 James R. Kang, Zahari N. Tchopev, H Samuel Scheuller et al.

Background: Nightmare disorder (NDO) is a clinically under-recognized sleep disorder within the military population. We have previously reported that 31.2% of patients referred to our sleep disorders center incidentally had probable NDO, yet only 3.9% were specifically referred for NDO. Under-recognition and therefore under-treatment of NDO negatively impacts patients' health and military...